

# NHS Fife submission of 18 October 2023

## PE2031/E: Provide insulin pumps to all children with type 1 diabetes in Scotland

In NHS Fife we currently have 251 patients with type 1 diabetes under the age of 18. We agree that all paediatric patients with type 1 diabetes should have access to insulin pump therapy. We also support the new NICE guidance that will be published later this year that paediatric patients have access to continuous glucose monitoring (CGM) and hybrid pump technology.

In NHS Fife we have worked hard at providing these technologies to our families and currently 70% of our patients are on insulin pump therapy & 71% of our patients using CGM. This is compared to the Scottish average for under 18's of 50.1% pump use and 44.2 % using CGM.

Our criteria for insulin pump therapy is that the young person is on insulin therapy. Within our current population those that are not on pump therapy are because either they do not want pump therapy or are early in their diagnosis and still learning about diabetes management, such as carbohydrate counting. We currently do not have a waiting list for paediatrics pump therapy. Once a family choose to move onto pump therapy the pump is ordered and training dates and on-boarding arranged with the specialist nurses.

We believe it important to be able to offer a choice with regard to pump therapy as the different systems all have their individual benefits and what is right for one person may not work for another. We currently provide Medtronic Pumps (680g & 780g), Tandem T-slim, Omnipod (Dash & 5), Ypsomed and Dana RS.

In order to get the maximum benefits from these technologies it is imperative that there are enough staff to support and educate patients and families in their use otherwise the full benefit of these systems will not be realised. We would ask that Scottish Government ensure that there is funding to meet the minimum staffing requirements as per the

ISPAD guidance (International society for paediatric and adolescent diabetes).

The combination of insulin pump therapy with CGM in the form of a hybrid closed loop pump is quickly becoming the main therapy in type 1 diabetes with its benefits in improved control and quality of life. National guidance is moving towards this being the mainstay of treatment for type 1 diabetes in the paediatric population.